Browse by Series:

FDA Approval Sought in Multiple Myeloma, 2017 AACR Annual Meeting Highlights, and More

Patrick Borgen, MD
Published Online: Thursday, Apr 13, 2017



Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non–small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
Slider Left
Slider Right


Patrick Borgen, MD, discusses an FDA approval sought for an agent in multiple myeloma, impressive phase III findings in non–small cell lung cancer, a change in USPSTF recommendations for PSA screening, and highlights from the 2017 AACR Annual Meeting.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Redefining Treatment Paradigms in the Management of Chronic Lymphocytic LeukemiaOct 05, 20172.0
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Publication Bottom Border
Border Publication